Welcome to our dedicated page for Proqr Therapeuti news (Ticker: PRQR), a resource for investors and traders seeking the latest updates and insights on Proqr Therapeuti stock.
ProQR Therapeutics (PRQR) is a clinical-stage biopharmaceutical company pioneering RNA-based therapies for severe genetic disorders. This page provides investors and industry observers with timely updates on clinical developments, regulatory milestones, and strategic partnerships related to its Axiomer RNA editing platform.
Access verified press releases and objective news coverage spanning key areas including clinical trial progress, research collaborations, and intellectual property advancements. Our curated collection ensures you stay informed about PRQR's work in addressing unmet medical needs through precise RNA modification technologies.
Discover updates on therapeutic programs targeting conditions like cystic fibrosis and Rett syndrome, financial disclosures, and partnership announcements with industry leaders. All content is sourced from official channels and reputable financial publications to maintain accuracy and compliance.
Bookmark this page for streamlined access to PRQR's latest scientific advancements and corporate updates. Check regularly for new developments in RNA editing innovation and the company's progress toward delivering transformative genetic medicines.
ProQR Therapeutics (Nasdaq: PRQR) announced its participation in the EURETINA virtual congress from September 9-12, 2021, where it will present data from the Phase 1/2 Stellar trial of its investigational RNA therapy QR-421a. This therapy targets vision loss due to mutations in the USH2A gene, the leading cause of combined deafness and blindness. The presentation, led by Dr. David G. Birch, will mark the first public data presentation from the Stellar trial.
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced participation in various upcoming investor conferences focused on RNA therapies for genetic eye diseases. Key events include:
- Citi’s 16th Annual BioPharma Virtual Conference on September 9, 4:10-4:55 pm EDT.
- HC Wainwright 23rd Annual Global Investment Conference available on demand from September 13, 7am EDT.
- Cantor Virtual Global Healthcare Conference on September 28, 3:20-3:50 pm EDT.
- Chardan’s 5th Annual Genetic Medicines Conference on October 5, 4:00-4:30 pm EDT.
Details are available on the company’s website.
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced that its management will present at the HC Wainwright Ophthalmology Virtual Conference. The presentation will be available on demand starting August 17, 2021, at 7:00 am EDT. An archived version will be accessible for 30 days on the company’s website. ProQR is committed to developing transformative RNA therapies for genetic eye diseases, leveraging its proprietary RNA repair technologies.
ProQR Therapeutics reported its Q2 2021 financial results, highlighting significant progress in its clinical trials and partnerships. The Illuminate trial of sepofarsen for LCA10 is set to release top-line data in H1 2022. The QR-421a trials for Usher syndrome and retinitis pigmentosa aim to start by year-end 2021, while initial data from the QR-1123 trial is expected in Q4 2021. Financially, ProQR had €139.4 million in cash as of June 30, 2021, with a net loss of €15.8 million for the quarter. New partnerships and a public offering bolstered its financial position.
ProQR Therapeutics (Nasdaq: PRQR) announced its management will present during a fireside chat at the JMP Securities Life Sciences Conference on June 17, 2021, from 3:00 to 3:25 pm EDT. The presentation will be available via a live webcast on ProQR's website under the Investors & Media section, with an archived version accessible for 30 days post-event. ProQR focuses on transformative RNA therapies for genetic eye diseases such as Leber congenital amaurosis 10 and Usher syndrome, utilizing proprietary RNA repair technologies.
ProQR Therapeutics reported significant progress in Q1 2021, completing enrollment for the pivotal Illuminate trial of sepofarsen for LCA10. Positive Phase 1/2 data for QR-421a was shared, with plans for two pivotal Phase 2/3 trials by year-end. The company secured $103.5 million from a public offering, bolstering its balance sheet for further clinical developments. Q1 2021 net loss was €12.6 million, improving from €16.1 million year-over-year. Upcoming milestones include top-line results from Illuminate anticipated in H1 2022.
Yarrow Biotechnology, formed by RTW Investments, has licensed ProQR Therapeutics' antisense oligonucleotide (ASO) technology for non-ophthalmology applications. ProQR stands to gain up to $115 million in upfront and milestone payments, alongside royalties on future sales. ProQR will also receive an undisclosed equity stake in Yarrow. The partnership aims to develop ASO-based therapies targeting disorders with significant unmet needs. Roderick Wong from RTW believes in the transformative potential of RNA-based therapies in genetically-defined diseases.
ProQR Therapeutics N.V. (Nasdaq:PRQR) announced a virtual presentation at ARVO on May 6, 2021, detailing data from its Phase 1/2 InSight trial of sepofarsen, aimed at treating Leber Congenital Amaurosis type 10 (LCA10). This presentation follows earlier discussions from July 2020, with new data expected in H2 2021. Currently, there are no approved treatments for LCA10, affecting around 2,000 individuals in the Western world. Sepofarsen is a pioneering RNA therapy addressing the underlying genetic cause, with significant designations from regulatory bodies.
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced its participation in the Kempen Life Sciences Conference 2021 on April 28, 2021, hosting 1x1 meetings. The company focuses on developing transformative RNA therapies for inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome, and retinitis pigmentosa. ProQR utilizes proprietary RNA repair platform technologies to advance its pipeline, emphasizing patient-centered approaches.
ProQR Therapeutics N.V. (Nasdaq: PRQR) will hold its Annual General Meeting of Shareholders on May 19, 2021, at 16:00 CET via videoconference. Relevant documents, including the meeting agenda, will be available in the 'Investors & Media' section of their website. ProQR is focused on developing transformative RNA therapies for inherited retinal diseases, aiming to improve the lives of patients with conditions like Leber congenital amaurosis and retinitis pigmentosa.
FAQ
What is the current stock price of Proqr Therapeuti (PRQR)?
What is the market cap of Proqr Therapeuti (PRQR)?
